News about Global Pharma

Sun Pharma Halts Development of SCD-044 After Phase 2 Trials Miss Efficacy Endpoints in Psoriasis and Atopic Dermatitis

Sun Pharma has announced that its Phase 2 trials for SCD-044 in psoriasis and atopic dermatitis did not meet primary efficacy endpoints of 75 percent improvement in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, prompting discontinuation of further development.

Global Pharma | 03/06/2025 | By Manvi |  222

Biocon Secures Approval for Diabetes Drug Liraglutide in India

Biocon Ltd. has received approval in India for its Liraglutide drug substance and drug product, marking a key milestone in expanding access to GLP-1 therapy for Type 2 diabetes.

Global Pharma | 03/06/2025 | By Manvi |  288

ASP Isotopes and Isotopia Ink Deal to Secure Gd-160 Supply for Cancer Therapy

This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.

Global Pharma | 02/06/2025 | By Manvi |  294

Zydus Secures Tentative Approval from USFDA for Rifaximin Tablets, 550 mg

Zydus Lifesciences has received tentative USFDA approval for Rifaximin Tablets, 550 mg, used to treat IBS-D in adults.

Global Pharma | 02/06/2025 | By Manvi |  237

Moderna Secures US FDA Approval for COVID-19 Vaccine mNEXSPIKE

Moderna has received FDA approval for mNEXSPIKE (mRNA-1283), its next-generation COVID-19 vaccine, for adults 65+ and at-risk individuals aged 12–64, ahead of the 2025–2026 respiratory virus season.

Global Pharma | 02/06/2025 | By Manvi |  235

Astellas Signs Exclusive Licensing Agreement with Evopoint Biosciences for Novel CLDN18.2-Targeting ADC XNW27011

Astellas Pharma has entered an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a clinical-stage antibody-drug conjugate targeting CLDN18.2 for the treatment of solid tumours.

Global Pharma | 31/05/2025 | By Manvi |  197

Eton Pharmaceuticals Secures US FDA Approval for KHINDIVI Oral Solution

Eton Pharmaceuticals has received FDA approval for KHINDIVI, the first and only oral hydrocortisone solution for paediatric patients aged 5 and older with adrenocortical insufficiency, offering precise, ready-to-use dosing without the need for tablet splitting.

Global Pharma | 31/05/2025 | By Manvi |  412

Terumo Launches ROADSAVER Carotid Stent System for Commercial Use

Terumo Interventional Systems (TIS), a division of Terumo Corporation, announces the early commercial availability of its FDA-approved ROADSAVER™ Carotid Stent System. Indicated for use with the Nanoparasol® Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events

Global Pharma | 28/05/2025 | By Manvi |  383

Olympus Receives FDA Clearance for EZ1500 Endoscopes with EDOF Technology

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced FDA 510(k) clearance of its EZ1500 series endoscopes featuring Extended Depth of Field (EDOF™) technology.

Global Pharma | 28/05/2025 | By Manvi |  408

Sandoz Introduces Pyzchiva Autoinjector, First Commercially Available in Europe for Ustekinumab Biosimilars

Sandoz has launched Pyzchiva, the first ustekinumab biosimilar autoinjector in Europe, aiming to enhance patient comfort and adherence in the treatment of chronic inflammatory diseases.

Global Pharma | 27/05/2025 | By Manvi |  281